Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with mFOLFOXIRI for Borderline Resectable Colorectal Liver Metastases
NCT03711240Phase 2Unknown
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jan 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in colorectal cancer (CRC), sponsored by National Cheng Kung University Hospital. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03711240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711240.